SPIEZIA, LUCA
 Distribuzione geografica
Continente #
NA - Nord America 13.776
AS - Asia 2.079
EU - Europa 2.058
AF - Africa 29
SA - Sud America 23
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 7
Totale 17.981
Nazione #
US - Stati Uniti d'America 13.743
SG - Singapore 1.104
CN - Cina 574
IT - Italia 450
FI - Finlandia 369
DE - Germania 349
FR - Francia 268
HK - Hong Kong 251
RU - Federazione Russa 165
SE - Svezia 151
VN - Vietnam 114
GB - Regno Unito 109
UA - Ucraina 65
NL - Olanda 39
IE - Irlanda 23
AT - Austria 22
CA - Canada 22
IN - India 16
BR - Brasile 15
EG - Egitto 15
MA - Marocco 10
CH - Svizzera 7
AU - Australia 6
BE - Belgio 5
EU - Europa 5
RO - Romania 5
CZ - Repubblica Ceca 4
PL - Polonia 4
DK - Danimarca 3
GR - Grecia 3
HN - Honduras 3
IL - Israele 3
JP - Giappone 3
MX - Messico 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
VE - Venezuela 3
AR - Argentina 2
BG - Bulgaria 2
CL - Cile 2
EE - Estonia 2
ES - Italia 2
KE - Kenya 2
LT - Lituania 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BJ - Benin 1
BS - Bahamas 1
CO - Colombia 1
HR - Croazia 1
HU - Ungheria 1
IQ - Iraq 1
IR - Iran 1
KZ - Kazakistan 1
LK - Sri Lanka 1
OM - Oman 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
TR - Turchia 1
UG - Uganda 1
UZ - Uzbekistan 1
Totale 17.981
Città #
Fairfield 2.281
Woodbridge 1.234
Chandler 1.041
Houston 967
Ashburn 965
Ann Arbor 811
Seattle 768
Cambridge 742
Wilmington 712
Singapore 679
Boardman 484
Princeton 406
Medford 352
Santa Clara 319
Des Moines 294
San Diego 287
Helsinki 255
Hong Kong 249
Jacksonville 214
Beijing 164
Roxbury 149
Padova 133
Dong Ket 114
Munich 84
Nanjing 66
New York 40
London 30
Hebei 29
Milan 29
Shenyang 26
Bologna 25
Nanchang 25
Nuremberg 25
Kharkiv 23
Norwalk 23
Los Angeles 22
Chicago 21
Dublin 20
Rome 19
Ogden 18
Jinan 17
Falls Church 16
Vienna 14
Borås 12
Guangzhou 12
Kilburn 12
Redwood City 11
Tianjin 11
Falkenstein 10
Jiaxing 10
Nürnberg 10
Redmond 10
Amsterdam 9
Dallas 9
Hangzhou 9
Lappeenranta 9
Mykolayiv 8
Shanghai 8
Chiswick 7
Kingston 7
Palermo 7
Verona 7
Washington 7
Cagliari 6
Naples 6
Tappahannock 6
Trieste 6
Zhengzhou 6
Cairo 5
Council Bluffs 5
Frankfurt am Main 5
Hefei 5
Jyväskylä 5
Kunming 5
Liverpool 5
North Bergen 5
Rockville 5
Turin 5
Acton 4
Alexandria 4
Basel 4
Changsha 4
Dearborn 4
Dronten 4
Genoa 4
Las Vegas 4
Nanning 4
Pune 4
Taiyuan 4
Toronto 4
Villafranca Padovana 4
Augsburg 3
Brussels 3
Campogalliano 3
Caracas 3
Detroit 3
Ferentino 3
Florence 3
Hounslow 3
Indiana 3
Totale 14.536
Nome #
Whole blood thromboelastometry profiles in women with preeclampsia 225
Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles? 202
Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients 177
Dynamics of circulating microparticles in obesity after weight loss 156
Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings. 141
Are thromboelastometric and thromboelastographic parameters associated with mortality in septic patients? A systematic review and meta-analysis 138
Acute oppressive chest pain in a 66-year-old woman with a recent Amplatzer device closure of patent foramen ovale 137
X-linked thrombophilia with a mutant factor IX (factor IX Padua). 137
Changes in plasma circulating microvesicles in patients with HCV‐related cirrhosis after treatment with direct‐acting antivirals 134
Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia 130
The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement 128
Microparticles as biomarkers of venous thromboembolic events 124
Does decreased fibrinolysis have a role to play in the development of non-neoplastic portal vein thrombosis in patients with hepatic cirrhosis? 123
Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis 123
null 122
Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms 121
Platelet factor V levels in moderate to severe congenital factor V deficiency. 121
Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S 121
ABO blood group and the risk of post-thrombotic syndrome 119
Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study 117
Whole blood rotation thromboelastometry (ROTEM(®)) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. 116
Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. 116
Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. 115
Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. 115
Uso della tromboelastometria (ROTEM) per ottimizzare la somministrazione di fibrinogeno (Haemocomplettan) nel sanguinamento critico intraoperatorio 115
Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. 113
Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. 111
Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events 111
Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery 111
Whole blood rotation thromboelastometry (ROTEM®) profiles in subjects with non-neoplastic portal vein thrombosis. 110
Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients 110
COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward 110
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. 110
New prothrombin mutation (Arg596Trp, Prothrombin Padua 2) associated with venous thromboembolism 109
Thromboelastometry guided fibrinogen replacement therapy in cardiac surgery: a retrospective observational study 109
Factor VIIa-antithrombin complexes in patients with non-neoplastic portal vein thrombosis with and without cirrhosis. 108
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein i antibodies. A comparison with a homemade ELISA method 108
Effects of long-term administration of recombinant human protein C in xenografted primates. 108
Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: A role for circulating microparticles? 107
Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth? 106
Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders 106
The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. 105
Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study 105
Similar hypercoagulable state and thrombosis risk in type I and type III proteinS-deficient individuals from mixed type I/III families. 104
Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women 104
Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases 104
Tailored prophylaxis with rFXIII (NovoThirteen ® ) in a young girl with severe FXIII deficiency and previous cephalohaematoma 104
Plasma fibrinolytic capacity in renal transplant recipients: Effect of steroid-free immunosuppression therapy. 103
Factor VIIa-antithrombin complexes in children with ischemic stroke. 102
Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke 101
On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI) 101
Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. 99
Endothelial damage of the portal vein is associated with Heparin-like effect in advanced stages of cirrhosis 99
Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct acting antivirals 98
More severe hypercoagulable state in acute COVID-19 pneumonia as compared to other pneumonia 98
The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology 97
“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate 95
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. 94
Factor VIIa-AT complex plasma levels and arterial thrombosis. 94
"Hypocoagulable" thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts? 94
COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure 94
Studio della sintesi del fattore V della coagulazione attraverso il modello sperimentale delle colture megacariocitarie ed il modello clinico delle famiglie con deficit ereditario di fattore V 94
Treatment of venous thromboembolism: the single-drug approach 93
Cardiopulmonary bypass-induced coagulopathy in paediatric patients: the Role of Platelets in postoperative bleeding. A preliminary study 92
Whole blood coagulation assessment using rotation thrombelastogram thromboelastometry in patients with acute deep vein thrombosis. 91
ABO blood groups and the risk of retinal vein occlusion 91
Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. 90
Thrombin activatable fibrinolysis inhibitor in cancer patients with and without venous thromboembolism. 90
The hazard of comparing apples and oranges: the proper indication for the use of recombinant activated clotting factor VII in cardiac surgery. 90
Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit 90
Idraparinux: review of its clinical efficacy and safety for prevention andtreatment of thromboembolic disorders. 89
Thrombophilia as a predictor of persistent residual vein thrombosis 89
The haemostatic system in acromegaly: a single-centre case–control study 89
Similar hypercoagulable state and thrombosis risk in type Iand type III protein S-deficient individuals from families with mixed type I/IIIprotein S deficiency. 88
Reference values for thromboelastometry (ROTEM®) in cynomolgus monkeys (Macaca fascicularis). 88
Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma 88
Thrombophilia and the risk of post-thrombotic syndrome: Retrospective cohort observation 88
The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope? 88
Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. 87
Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. 87
Thrombophilia, risk factors and prevention 87
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. 87
Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis 87
Inherited thrombophilia and venous thromboembolism 86
Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients 86
Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. 85
Outcome of long-term prophylaxis after cerebral hemorrhage in a patient with severe hemophilia B. 85
Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivitis. 85
Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rpFVIII (Obizur®) 85
Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors 84
Association between increased FVIIa-antithrombin complex/FVIIa ratio and pre-eclampsia. 84
Thromboelastometry profiles after “in vitro” addition of a new plasma-derived factor V concentrate to whole blood from parahaemophilia patients 84
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation 82
Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma 81
Prothrombin mutation conveying antithrombin resistance. 81
Circulating microparticles in carriers of prothrombin G20210A mutation. 81
The prognostic role of ThromboDynamic Index in patients with severe sepsis 81
Whole blood rotation thrombelastometry in subjects undergoing vitamin K antagonist treatment: hypo- or hypercoagulable profiles? 80
Freedom solo stentless aortic valve: quantitative and qualitative assessment of thrombocytopenia. 80
Partial F8 gene duplication (Factor VIII Padua) associated with high factor VIII levels and familial thrombophilia 80
Totale 10.488
Categoria #
all - tutte 84.999
article - articoli 67.372
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 101
Totale 152.472


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020815 0 0 0 0 0 0 0 0 347 239 119 110
2020/20212.664 76 158 163 187 241 92 103 259 248 251 189 697
2021/20223.917 94 808 325 264 146 219 111 416 150 108 274 1.002
2022/20232.324 666 228 50 255 325 260 6 136 238 24 112 24
2023/20241.476 50 173 147 137 85 168 79 54 38 74 218 253
2024/20253.310 43 515 421 176 832 201 341 582 199 0 0 0
Totale 18.415